| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A graph model of combination therapies
|
Sang, Mengmeng
|
|
|
27 |
5 |
p. 1210-1217
|
article
|
| 2 |
An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition
|
Hu, Liqing
|
|
|
27 |
5 |
p. 1457-1463
|
article
|
| 3 |
A novel approach for quantification of the future unmet medical need in right ventricular dysfunction
|
Schramm, Lena K.
|
|
|
27 |
5 |
p. 1326-1331
|
article
|
| 4 |
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020
|
Wang, Shuhang
|
|
|
27 |
5 |
p. 1236-1250
|
article
|
| 5 |
Applications of density functional theory in COVID-19 drug modeling
|
Ye, Naike
|
|
|
27 |
5 |
p. 1411-1419
|
article
|
| 6 |
Applications of quantitative social media listening to patient-centric drug development
|
Schmidt, Ana Lucía
|
|
|
27 |
5 |
p. 1523-1530
|
article
|
| 7 |
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates
|
Medina-Franco, José L.
|
|
|
27 |
5 |
p. 1420-1430
|
article
|
| 8 |
Compound–protein interaction prediction by deep learning: Databases, descriptors and models
|
Du, Bing-Xue
|
|
|
27 |
5 |
p. 1350-1366
|
article
|
| 9 |
Contents page
|
|
|
|
27 |
5 |
p. i-iii
|
article
|
| 10 |
Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy
|
Ganji, Chaithanya
|
|
|
27 |
5 |
p. 1404-1410
|
article
|
| 11 |
Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors
|
Niu, Yuzhen
|
|
|
27 |
5 |
p. 1464-1473
|
article
|
| 12 |
Dendrimer nanoplatforms for veterinary medicine applications: A concise overview
|
Mignani, Serge
|
|
|
27 |
5 |
p. 1251-1260
|
article
|
| 13 |
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
|
Ahamad, Shakir
|
|
|
27 |
5 |
p. 1332-1349
|
article
|
| 14 |
Discovery solubility measurement and assessment of small molecules with drug development in mind
|
Barrett, Jaclyn A.
|
|
|
27 |
5 |
p. 1315-1325
|
article
|
| 15 |
Emerging trends in pulmonary delivery of biopharmaceuticals
|
Kunde, Shalvi Sinai
|
|
|
27 |
5 |
p. 1474-1482
|
article
|
| 16 |
Exclusive modifications of NuMA in malignant epithelial cells: A potential therapeutic mechanism
|
Cohen-Armon, Malka
|
|
|
27 |
5 |
p. 1205-1209
|
article
|
| 17 |
Experimental murine models of brainstem gliomas
|
Ni, Shuting
|
|
|
27 |
5 |
p. 1218-1235
|
article
|
| 18 |
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
|
Dujardin, Pieter
|
|
|
27 |
5 |
p. 1261-1283
|
article
|
| 19 |
Functionalizing nanofibrous platforms for neural tissue engineering applications
|
Lategan, Michelle
|
|
|
27 |
5 |
p. 1381-1403
|
article
|
| 20 |
Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: A case for ARDS therapy development
|
Kayyali, Usamah S.
|
|
|
27 |
5 |
p. 1448-1456
|
article
|
| 21 |
Maximizing data value for biopharma through FAIR and quality implementation: FAIR plus Q
|
Harrow, Ian
|
|
|
27 |
5 |
p. 1441-1447
|
article
|
| 22 |
Methodological advances in the design of peptide-based vaccines
|
Kalita, Parismita
|
|
|
27 |
5 |
p. 1367-1380
|
article
|
| 23 |
Recent advances in developing polymeric micelles for treating cancer: Breakthroughs and bottlenecks in their clinical translation
|
Kaur, Jaskiran
|
|
|
27 |
5 |
p. 1495-1512
|
article
|
| 24 |
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases
|
Mishra, Neeraj
|
|
|
27 |
5 |
p. 1431-1440
|
article
|
| 25 |
Tau protein aggregation: Key features to improve drug discovery screening
|
Giovannini, Johanna
|
|
|
27 |
5 |
p. 1284-1297
|
article
|
| 26 |
The changing landscape of treatment options in childhood acute lymphoblastic leukaemia
|
Micallef, Benjamin
|
|
|
27 |
5 |
p. 1483-1494
|
article
|
| 27 |
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options
|
Nakhjavani, Maryam
|
|
|
27 |
5 |
p. 1298-1314
|
article
|
| 28 |
Zebrafish as a powerful alternative model organism for preclinical investigation of nanomedicines
|
Ruchika,
|
|
|
27 |
5 |
p. 1513-1522
|
article
|
Journal description